Dr. Peter Meintjes served as a Chief Commercial Officer at Transplant Genomics, Inc., since April 2020. he serves as CEO at Pacific Edge Limited since January 17, 2022. He was responsible for leding the co...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Peter Meintjes	Chief Executive Officer	2.4yrs	データなし	0.048% NZ$ 34.0k
Grant Gibson	Chief Financial Officer	4.5yrs	データなし	0.011% NZ$ 7.8k
Darrell Morgan	Chief Operating Officer	1.7yrs	データなし	データなし
Justin Harvey	Chief Technology Officer	4.4yrs	データなし	データなし
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	データなし
Andrew McIntosh	Chief Digital Officer	3yrs	データなし	データなし
Glen Costin	President of Asia Pacific	no data	データなし	データなし
Tamer Aboushwareb	Chief Medical Officer	no data	データなし	データなし
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	データなし

2.7yrs

平均在職期間

経験豊富な経営陣: PEBの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	データなし
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	データなし
R. Spence	Member of Scientific Advisory Board	no data	データなし	データなし
Chris Gallaher	Independent Non-Executive Chairman of the Board	7.9yrs	NZ$115.00k	0.12% NZ$ 88.0k
Osamu Ogawa	Member of Scientific Advisory Board	no data	データなし	データなし
Bryan Raymond Williams	Member of Scientific Advisory Board & Independent Deputy Non-Executive Chairman	11yrs	NZ$70.00k	0.075% NZ$ 53.7k
Michael Sullivan	Member of Scientific Advisory Board	no data	データなし	データなし
Nikola Kasabov	Member of Scientific Advisory Board	no data	データなし	データなし
Murray Brennan	Member of Scientific Advisory Board	no data	データなし	データなし
Anatole G. Masfen	Independent Non-Executive Director	16.2yrs	NZ$60.00k	1.15% NZ$ 820.2k
Anna Stove	Independent Non-Executive Director	3.3yrs	NZ$60.00k	0.00062% NZ$ 442.6
Sarah Park	Independent Non-Executive Director	5.5yrs	NZ$70.00k	0.0072% NZ$ 5.2k

7.9yrs

平均在職期間

75yo

平均年齢

経験豊富なボード: PEBの取締役会は経験豊富であると考えられます ( 7.9年の平均在任期間)。

Pacific Edge マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Recent updates

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Consensus EPS estimates upgraded to NZ$0.034 loss

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Price target decreased by 7.8% to NZ$0.15

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

Consensus forecasts updated

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Price target decreased to NZ$0.61

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Price target decreased to NZ$0.72

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Consensus revenue estimates fall by 27%

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

Now 26% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NZ$1.11

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Consensus forecasts updated

Price target decreased to NZ$1.32

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Insufficient new directors

Consensus revenue estimates fall to NZ$12.9m

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

CEO, MD & Executive Director exercised options to buy NZ$478k worth of stock.

Consensus EPS estimates fall to -NZ$0.014

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Full year 2021 earnings released: NZ$0.02 loss per share (vs NZ$0.032 loss in FY 2020)

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Insider recently sold NZ$130k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Insider recently sold NZ$120k worth of stock

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Analysts update estimates

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Pacific Edge Limited, Annual General Meeting, Jul 29, 2021

Pacific Edge Limited to Report First Half, 2022 Results on Nov 26, 2021

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

New 90-day high: NZ$1.08

New 90-day high: NZ$0.78

First half 2021 earnings released: NZ$0.01 loss per share

Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?

Pacific Edge Limited Announces Management Changes

Pacific Edge Diagnostics Notifies the CMS LCD Coverage for Cxbladder

Pacific Edge Limited to Report Q2, 2021 Results on Nov 26, 2020

Insider recently sold NZ$258.2k worth of stock

Pacific Edge Limited announced that it expects to receive NZD 22 million in funding from ANZ New Zealand Investments Limited

マネジメント基準チェック /24